Combination therapy can reduce recurrence of small, HER2-positive breast tumors

[News]

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

More... (http://www.news-medical.net/news/20150108/Combination-therapy-can-reduce-recurrence-of-small-HER2-positive-breast-tumors.aspx)